CERO THERAPEUTICS HOLDINGS, INC. (CERO): debt financing — Phoenix Biotech Acquisition Corp. boosts sponsor note limit to $1.6M from $1.5M

CERO THERAPEUTICS HOLDINGS, INC.

First Amendment to Promissory Note raises maximum principal from $1.5M to $1.6M.
Approximately $1.4M had been drawn under the note as of December 8, 2023.
All other material terms unchanged; note matures upon consummation of initial business combination.
Note is with sponsor Phoenix Biotech Sponsor, LLC; executed December 8, 2023.

item 1.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. amended loan of $1,600,000 with Phoenix Biotech Sponsor, LLC.

Instrument: loan
Principal: $1,600,000
Counterparty: Phoenix Biotech Sponsor, LLC
Event: amendment

Exact text from the filing

On December 8, 2023, the Company and the Lender amended the Promissory Note to increase the aggregate principal amount of the Promissory Note from $1,500,000 to $1,600,000.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. amended Promissory Note with Phoenix Biotech Sponsor, LLC valued at $1,500,000 to $1,600,000 (effective 2023-12-08).

Action: amendment
Agreement: credit facility
Counterparty: Phoenix Biotech Sponsor, LLC
Value: $1,500,000 to $1,600,000
Effective: 2023-12-08

Exact text from the filing

On December 8, 2023, the Company and the Lender amended the Promissory Note to increase the aggregate principal amount of the Promissory Note from $1,500,000 to $1,600,000.

View on SEC.gov

101 debt financings filed in the last 30 days. Browse all debt financings →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-094779

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.